Business

Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia

Designated Territories will include Kingdom of Saudi Arabia.CH Trading Group will continue the process to expand commercialization of ZTlido® in Middle East

articleScilex Holding CompanyMay 31, 20233/company/scilex-holding-company/news/scilex-holding-company-enters-master-distributor-agreement-among-ch-trading-group-llc-cht-or-territories-distributor-and-farouk-maamoun-tamer-and-co-master-distributor-for-the-distribution-of-ztlidor-in-the-kingdom-of-saudi-arabia
Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia

About this update from Scilex Holding Company

[{"type":"text","content":"Designated Territories will include Kingdom of Saudi Arabia.CH Trading Group will continue the process to expand commercialization of ZTlido® in Middle East and North Africa markets and has the opportunity to distribute across the broader Islamic world and further expand the relationship for other products in Scilex’s non-opioid pain portfolio. PALO ALTO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of ZTlido® in Kingdom of Saudi Arabia. ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN). ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. “We are pleased to announce the master distributor agreement with Scilex to bring to the people of KSA a non-opioid alternative for pain management due to the risk of addiction associated with the prolonged use of prescription opioids,” said Dr. Yasser Khattab, Chief Executive Officer of Tamer Healthcare. “We aim to be vertically integrated, including having the ability to conduct future research & development in tandem with partner companies such as Scilex,” added Dr. Ahmed Mousa, Business Development Head at Tamer Healthcare. “This agreement represents another critical milestone towards bringing our innovative non-opioid pain management medicines to people around the world,” said Jaisim Shah, President and Chief Executive Officer of Scilex. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maxim...

More updates from Scilex Holding Company